



## King's Research Portal

DOI:

[10.1002/hep.26583](https://doi.org/10.1002/hep.26583)

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Grant, C. R., Liberal, R., Holder, B. S., Cardone, J., Ma, Y., Robson, S. C., Mieli-Vergani, G., Vergani, D., & Longhi, M. S. (2014). Dysfunctional CD39(POS) Regulatory T Cells and Aberrant Control of T-Helper Type 17 Cells in Autoimmune Hepatitis. *Hepatology*, 59(3), 1007-1015. <https://doi.org/10.1002/hep.26583>

### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### Take down policy

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

**Table 1. Autoimmune hepatitis patient demographics and laboratory data**

	#	% female	Age (years)	AST (nv: <50 IU/L)	Bilirubin (nv: <20 $\mu$ mol/L)	IgG (nv: 6.5-17g/L)	% ANA positive (median)	% SMA positive (median)
<b>Active disease</b>	14	71	12 (9-18)	112 (54-1074)**	25 (8-82)**	15.6 (2.4-25.9)*	44 (1/40)	33 (1/640)
• <b>Near presentation†</b>	9	78	11 (9-15)	117 (61-1074)	39 (8-82)	19.0 (2.4-25.9)	60 (1/40)	40 (1/400)
• <b>Relapse</b>	5	60	12 (9-18)	87 (54-224)	14 (10-24)	14.0 (10.0-19.5)	0	25 (1/640)
<b>Remission</b>	27	55	15 (6-27)	27 (16-46)	9 (4-42)	10.7 (0.9-19.0)	9 (1/60)	9 (1/120)

Data are presented as median (range) unless otherwise stated. Abbreviations: #, number; AST, aspartate aminotransferase; nv, normal value; ANA, anti-nuclear antibody; SMA, smooth muscle antibody

† 4 patients were studied before starting treatment and 5 were studied after treatment initiation but before the normalisation of AST levels

\*\* $P<0.005$ , \* $P<0.05$  comparing AST, bilirubin and IgG levels in patients with active disease and those at remission